Abstract:Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and programmed cell death (PD)-1. In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies have demonstrated survival benefits in numerous cancers, including melanoma and non-small-cell lung carcinoma. PD-1-expressing CD8+ T lymphocytes appear to play a major role in the response to these immune checkpoint inhibitors (ICI). Cytotoxic T lymphocytes (CTL) eliminate malignant cells through recognition by the T-cell receptor (TCR) of specific antigenic peptides presented on the surface of cancer cells by major histocompatibility complex class I/beta-2-microglobulin complexes, and through killing of target cells, mainly by releasing the content of secretory lysosomes containing perforin and granzyme B. T-cell adhesion molecules and, in particular, lymphocyte-function-associated antigen-1 and CD103 integrins, and their cognate ligands, respectively, intercellular adhesion molecule 1 and E-cadherin, on target cells, are involved in strengthening the interaction between CTL and tumor cells. Tumor-specific CTL have been isolated from tumor-infiltrating lymphocytes and peripheral blood lymphocytes (PBL) of patients with varied cancers. TCRβ-chain gene usage indicated that CTL identified in vitro selectively expanded in vivo at the tumor site compared to autologous PBL. Moreover, functional studies indicated that these CTL mediate human leukocyte antigen class I-restricted cytotoxic activity toward autologous tumor cells. Several of them recognize truly tumor-specific antigens encoded by mutated genes, also known as neoantigens, which likely play a key role in antitumor CD8 T-cell immunity. Accordingly, it has been shown that the presence of T lymphocytes directed toward tumor neoantigens is associated with patient response to immunotherapies, including ICI, adoptive cell transfer, and dendritic cell-based vaccines. These tumor-specific mutation-derived antigens open up new perspectives for development of effective second-generation therapeutic cancer vaccines.

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

Genetically engineered T cells for cancer immunotherapy

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Whole-exome Sequencing Predicted Cancer Epitope Trees of 23 Early Cervical Cancers in Chinese Women

312P Identification of Neoantigen-Specific T Cell Response and Anti-Tumour Immunity in Pancreatic Cancer

Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment

Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Landscape of Tumor Antigens in T Cell Immunotherapy

Adoptive cell transfer as personalized immunotherapy for human cancer

Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application

Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

Novel Tumor-Specific Antigens for Immunotherapy Identified From Multi-omics Profiling in Thymic Carcinomas

Antitumor Activity from Antigen-Specific CD8 T Cells Generated in Vivo from Genetically Engineered Human Hematopoietic Stem Cells

Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4– T Cells

CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy

Tumor-Specific CD4<SUP>+</SUP> T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4<SUP>-</SUP> T Cells